The pathogenesis of systemic lupus erythematosus-an update

Current Opinion in Immunology

Volumn 24, Issue 6, 2012, Pages 651-657

  Choi, Jinyoung ^a   Kim, Sang Taek ^a   Craft, Joe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BELIMUMAB; GLUCOCORTICOID; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DENDRITIC CELL; GERMINAL CENTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTERFERON PRODUCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; NEUTROPHIL; NONHUMAN; REMISSION; REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; WEIGHT GAIN;

AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNITY, INNATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 84869881059     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.10.004     Document Type: Review

References (81)

1. Shlomchik M.J., Craft J.E., Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001, 1:147-153.
2. Delgado-Vega A., Sánchez E., Löfgren S., Castillejo-López C., Alarcón-Riquelme M.E. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol 2010, 22:698-705.
3. Deng Y., Tsao B.P. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 2010, 6:683-692.
4. Taylor K.E., Chung S.A., Graham R.R., Ortmann W.A., Lee A.T., Langefeld C.D., Jacob C.O., Kamboh M.I., Alarcon-Riquelme M.E., Tsao B.P., et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet 2011, 7:e1001311.
5. Bronson P.G., Chaivorapol C., Ortmann W., Behrens T.W., Graham R.R. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 2012, 24:530-537.
6. Craft J.E. Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci Transl Med 2011, 3:73ps79.
7. Teichmann L.L., Ols M.L., Kashgarian M., Reizis B., Kaplan D.H., Shlomchik M.J. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010, 33:967-978.
8. William J., Euler C., Christensen S., Shlomchik M.J. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002, 297:2066-2070.
9. Hoyer B.F., Moser K., Hauser A.E., Peddinghaus A., Voigt C., Eilat D., Radbruch A., Hiepe F., Manz R.A. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004, 199:1577-1584.
10. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
11. Herlands R.A., Christensen S.R., Sweet R.A., Hershberg U., Shlomchik M.J. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008, 29:249-260.
12. Liu Z., Zou Y., Davidson A. Plasma cells in systemic lupus erythematosus: the long and short of it all. Eur J Immunol 2011, 41:588-591.
13. Mathian A., Gallegos M., Pascual V., Banchereau J., Koutouzov S. Interferon-alpha induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZBxNZW)F1 mice but not in BALB/c mice. Eur J Immunol 2011, 41:863-872.
14. Shlomchik M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008, 28:18-28.
15. Qi H., Egen J.G., Huang A.Y., Germain R.N. Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 2006, 312:1672-1676.
16. Chappell C.P., Draves K.E., Giltiay N.V., Clark E.A. Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. J Exp Med 2012, 209:1825-1840.
17. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
18. Ronnblom L., Alm G.V. The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol 2002, 63:1181-1193.
19. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
20. Niewold T.B., Kelly J.A., Kariuki S.N., Franek B.S., Kumar A.A., Kaufman K.M., Thomas K., Walker D., Kamp S., Frost J.M., et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 2012, 71:463-468.
21. Niewold T.B. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 2011, 31:887-892.
22. Lo M.S., Tsokos G.C. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci 2012, 1247:138-152.
23. Merrill J.T., Wallace D.J., Petri M., Kirou K.A., Yao Y., White W.I., Robbie G., Levin R., Berney S.M., Chindalore V., et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011, 70:1905-1913.
24. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J: Safety and pharmacodynamic results of rontalizumab in a phase i, placebo controlled, double blind, dose escalation study in systemic lupus erythematosus. Arthritis Rheum 2012 Jul 25. [Epub ahead of print]. doi:10.1002/art.34632.
25. Mathian A., Amoura Z., Adam E., Colaone F., Hoekman M.F., Dhellin O., Vandepapeliere P., Haroche J., Piette J.C., Lebon P., et al. Active immunisation of human interferon alpha transgenic mice with a human interferon alpha Kinoid induces antibodies that neutralise interferon alpha in sera from patients with systemic lupus erythematosus. Ann Rheum Dis 2011, 70:1138-1143.
26. Kaplan M.J. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011, 7:691-699.
27. Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Lin A.M., Rubin C.J., Zhao W., Olsen S.H., Klinker M., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011, 187:538-552.
28. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
29. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra19.
30. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., Punaro M., Baisch J., Guiducci C., Coffman R.L., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
31. Barrat F.J., Coffman R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008, 223:271-283.
32. De Bosscher K., Vanden Berghe W., Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003, 24:488-522.
33. Guiducci C., Gong M., Xu Z., Gill M., Chaussabel D., Meeker T., Chan J.H., Wright T., Punaro M., Bolland S., et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010, 465:937-941.
34. Chan O.T., Madaio M.P., Shlomchik M.J. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999, 169:107-121.
35. Crispin J.C., Kyttaris V.C., Terhorst C., Tsokos G.C. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:317-325.
36. Coca A., Sanz I. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 2012, 24:451-456.
37. Cappione A., Anolik J.H., Pugh-Bernard A., Barnard J., Dutcher P., Silverman G., Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005, 115:3205-3216.
38. Wardemann H., Nussenzweig M.C. B-cell self-tolerance in humans. Adv Immunol 2007, 95:83-110.
39. Menard L., Saadoun D., Isnardi I., Ng Y.S., Meyers G., Massad C., Price C., Abraham C., Motaghedi R., Buckner J.H., et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011, 121:3635-3644.
40. Jenks S.A., Sanz I: Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009, 8:209-213.
41. Anders H.J. A Toll for lupus. Lupus 2005, 14:417-422.
42. Liu Z., Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011, 32:388-394.
43. Moulton V.R., Tsokos G.C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:207.
44. Mietzner B., Tsuiji M., Scheid J., Velinzon K., Tiller T., Abraham K., Gonzalez J.B., Pascual V., Stichweh D., Wardemann H., et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA 2008, 105:9727-9732.
45. Shlomchik M.J., Aucoin A.H., Pisetsky D.S., Weigert M.G. Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc Natl Acad Sci USA 1987, 84:9150-9154.
46. Ravirajan C.T., Rahman M.A., Papadaki L., Griffiths M.H., Kalsi J., Martin A.C., Ehrenstein M.R., Latchman D.S., Isenberg D.A. Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol 1998, 28:339-350.
47. Grammer A.C., Slota R., Fischer R., Gur H., Girschick H., Yarboro C., Illei G.G., Lipsky P.E. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520.
48. Shlomchik M.J., Madaio M.P., Ni D., Trounstein M., Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994, 180:1295-1306.
49. Fazilleau N., Mark L., McHeyzer-Williams L.J., McHeyzer-Williams M.G. Follicular helper T cells: lineage and location. Immunity 2009, 30:324-335.
50. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
51. Linterman M.A., Rigby R.J., Wong R.K., Yu D., Brink R., Cannons J.L., Schwartzberg P.L., Cook M.C., Walters G.D., Vinuesa C.G. Follicular helper T cells are required for systemic autoimmunity. J Exp Med 2009, 206:561-576.
52. Odegard J.M., Marks B.R., DiPlacido L.D., Poholek A.C., Kono D.H., Dong C., Flavell R.A., Craft J. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med 2008, 205:2873-2886.
53. Bubier J.A., Sproule T.J., Foreman O., Spolski R., Shaffer D.J., Morse H.C., Leonard W.J., Roopenian D.C. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 2009, 106:1518-1523.
54. William J., Euler C., Shlomchik M.J. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol 2005, 174:6879-6887.
55. Simpson N., Gatenby P.A., Wilson A., Malik S., Fulcher D.A., Tangye S.G., Manku H., Vyse T.J., Roncador G., Huttley G.A., et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010, 62:234-244.
56. Terrier B., Costedoat-Chalumeau N., Garrido M., Geri G., Rosenzwajg M., Musset L., Klatzmann D., Saadoun D., Cacoub P. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol 2012, 39:1819-1828.
57. Morita R., Schmitt N., Bentebibel S.E., Ranganathan R., Bourdery L., Zurawski G., Foucat E., Dullaers M., Oh S., Sabzghabaei N., et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011, 34:108-121.
58. Grammer A.C., Lipsky P.E. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003, 5(Suppl 4):S22-S27.
59. Poholek A.C., Hansen K., Hernandez S.G., Eto D., Chandele A., Weinstein J.S., Dong X., Odegard J.M., Kaech S.M., Dent A.L., et al. In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol 2010, 185:313-326.
60. Robles-Carrillo L., Meyer T., Hatfield M., Desai H., Davila M., Langer F., Amaya M., Garber E., Francis J.L., Hsu Y.M., et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010, 185:1577-1583.
61. Vinuesa C.G., Sanz I., Cook M.C. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009, 9:845-857.
62. Schiffer L., Sinha J., Wang X., Huang W., von Gersdorff G., Schiffer M., Madaio M.P., Davidson A. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003, 171:489-497.
63. Manderson A.P., Botto M., Walport M.J. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004, 22:431-456.
64. Bergtold A., Gavhane A., D'Agati V., Madaio M., Clynes R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol 2006, 177:7287-7295.
65. Masutani K., Akahoshi M., Tsuruya K., Tokumoto M., Ninomiya T., Kohsaka T., Fukuda K., Kanai H., Nakashima H., Otsuka T., et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001, 44:2097-2106.
66. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., Theofilopoulos A.N. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788.
67. Hron J.D., Peng S.L. Type I IFN protects against murine lupus. J Immunol 2004, 173:2134-2142.
68. Atta A.M., Santiago M.B., Guerra F.G., Pereira M.M., Sousa Atta M.L. Autoimmune response of IgE antibodies to cellular self-antigens in systemic Lupus Erythematosus. Int Arch Allergy Immunol 2010, 152:401-406.
69. Charles N., Hardwick D., Daugas E., Illei G.G., Rivera J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010, 16:701-707.
70. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189:1639-1648.
71. Ahuja A., Shupe J., Dunn R., Kashgarian M., Kehry M.R., Shlomchik M.J. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007, 179:3351-3361.
72. Bekar K.W., Owen T., Dunn R., Ichikawa T., Wang W., Wang R., Barnard J., Brady S., Nevarez S., Goldman B.I., et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum 2010, 62:2443-2457.
73. Ahuja A., Teichmann L.L., Wang H., Dunn R., Kehry M.R., Shlomchik M.J. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupus. J Immunol 2011, 187:3888-3894.
74. Ramos-Casals M., Roberto Perez A., Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
75. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., Utset T.O., Gordon C., Isenberg D.A., Hsieh H.J., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
76. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., Maciuca R., Zhang D., Garg J.P., Brunetta P., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226.
77. Petri M., Stohl W., Chatham W., McCune W.J., Chevrier M., Ryel J., Recta V., Zhong J., Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459.
78. Collins C.E., Gavin A.L., Migone T.S., Hilbert D.M., Nemazee D., Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006, 8:R6.
79. Jacobi A.M., Huang W., Wang T., Freimuth W., Sanz I., Furie R., Mackay M., Aranow C., Diamond B., Davidson A. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210.
80. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., Li E.K., Thomas M., Kim H.Y., Leon M.G., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
81. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzova D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.